Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Biosensors to monitor MS activity.

Graves JS, Montalban X.

Mult Scler. 2020 Jan 22:1352458519888178. doi: 10.1177/1352458519888178. [Epub ahead of print]

PMID:
31965896
2.

The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis.

Gómez-Fernández P, Lopez de Lapuente Portilla A, Astobiza I, Mena J, Urtasun A, Altmann V, Matesanz F, Otaegui D, Urcelay E, Antigüedad A, Malhotra S, Montalban X, Castillo-Triviño T, Espino-Paisán L, Aktas O, Buttmann M, Chan A, Fontaine B, Gourraud PA, Hecker M, Hoffjan S, Kubisch C, Kümpfel T, Luessi F, Zettl UK, Zipp F, Alloza I, Comabella M, Lill CM, Vandenbroeck K.

Cells. 2020 Jan 10;9(1). pii: E175. doi: 10.3390/cells9010175.

3.

CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases.

Rotstein DL, Sawicka K, Bharatha A, Montalban X, Lipton JH.

Mult Scler. 2019 Dec 17:1352458519892914. doi: 10.1177/1352458519892914. [Epub ahead of print]

PMID:
31845621
4.

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.

Kalkers NF, Galan I, Kerbrat A, Tacchino A, Kamm CP, O'Connell K, McGuigan C, Edan G, Montalban X, Uitdehaag BM, Mokkink LB.

Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450. [Epub ahead of print]

PMID:
31845614
5.

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC.

Berger T, Brochet B, Brambilla L, Giacomini PS, Montalbán X, Vasco Salgado A, Su R, Bretagne A.

Mult Scler J Exp Transl Clin. 2019 Dec 2;5(4):2055217319887191. doi: 10.1177/2055217319887191. eCollection 2019 Oct-Dec.

6.

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, Ortí G, Holgado-Martín E, García-Vidal C, Vizcaya-Morales C, Martín-Vázquez V, González-Gay MÁ.

Autoimmun Rev. 2020 Jan;19(1):102429. doi: 10.1016/j.autrev.2019.102429. Epub 2019 Nov 15. Review.

7.

Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.

Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira À, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Bisecco A, Gass A, Eisele P, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Comi G, Filippi M; MAGNIMS Study Group.

Neurology. 2019 Nov 12;93(20):e1852-e1866. doi: 10.1212/WNL.0000000000008466. Epub 2019 Oct 14.

PMID:
31611336
8.

The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS.

Tintore M, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Río J, Tur C, Comabella M, Nos C, Arévalo MJ, Anglada E, Menendez R, Midaglia L, Galán I, Vidal-Jordana A, Castilló J, Mulero P, Zabalza A, Rodríguez-Acevedo B, Rodriguez M, Espejo C, Sequeira J, Mitjana R, de Barros A, Pareto D, Auger C, Pérez-Hoyos S, Sastre-Garriga J, Rovira A, Montalban X.

Mult Scler. 2019 Oct 15:1352458519877810. doi: 10.1177/1352458519877810. [Epub ahead of print]

PMID:
31610739
9.

Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M.

J Med Internet Res. 2019 Oct 8;21(10):e16287. doi: 10.2196/16287.

10.

Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.

Tur C, Kalincik T, Oh J, Sormani MP, Tintoré M, Butzkueven H, Montalban X.

Neurology. 2019 Oct 29;93(18):793-809. doi: 10.1212/WNL.0000000000008319. Epub 2019 Oct 7. Review.

PMID:
31591277
11.

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study.

Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium.

Mult Scler J Exp Transl Clin. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep.

12.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.

PMID:
31492652
13.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.

PMID:
31492651
14.

Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M.

J Med Internet Res. 2019 Aug 30;21(8):e14863. doi: 10.2196/14863. Erratum in: J Med Internet Res. 2019 Oct 8;21(10):e16287.

15.

Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.

Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Kappos L, Montalban X, Rovira À, Evangelou N, Wuerfel J; MAGNIMS Study Group.

JAMA Neurol. 2019 Aug 19. doi: 10.1001/jamaneurol.2019.2478. [Epub ahead of print]

PMID:
31424490
16.

Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care.

Saposnik G, Mamdani M, Montalban X, Terzaghi M, Silva B, Saladino ML, Tobler PN, Caceres F.

MDM Policy Pract. 2019 Jun 21;4(1):2381468319855642. doi: 10.1177/2381468319855642. eCollection 2019 Jan-Jun.

17.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis.

Peroni S, Sorosina M, Malhotra S, Clarelli F, Osiceanu AM, Ferrè L, Roostaei T, Rio J, Midaglia L, Villar LM, Álvarez-Cermeño JC, Guaschino C, Radaelli M, Citterio L, Lechner-Scott J, Spataro N, Navarro A, Martinelli V, Montalban X, Weiner HL, de Jager P, Comi G, Esposito F, Comabella M, Martinelli-Boneschi F.

Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428. [Epub ahead of print]

PMID:
31221001
18.

Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria.

Arrambide G, Tintore M, Montalban X.

Mult Scler. 2019 Oct;25(12):1690-1691. doi: 10.1177/1352458519846103. Epub 2019 May 16. No abstract available.

PMID:
31094275
19.

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group.

N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10.

PMID:
31075187
20.

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C.

Mult Scler. 2019 May 8:1352458519845844. doi: 10.1177/1352458519845844. [Epub ahead of print]

PMID:
31066634
21.

The Central Vein Sign in Radiologically Isolated Syndrome.

Suthiphosuwan S, Sati P, Guenette M, Montalban X, Reich DS, Bharatha A, Oh J.

AJNR Am J Neuroradiol. 2019 May;40(5):776-783. doi: 10.3174/ajnr.A6045. Epub 2019 Apr 18.

22.

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.

Rotstein D, Montalban X.

Nat Rev Neurol. 2019 May;15(5):287-300. doi: 10.1038/s41582-019-0170-8. Review.

PMID:
30940920
23.

Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?

Saposnik G, Maurino J, Sempere AP, Terzaghi MA, Amato MP, Montalban X.

Mult Scler J Exp Transl Clin. 2019 Mar 18;5(1):2055217319835226. doi: 10.1177/2055217319835226. eCollection 2019 Jan-Mar.

24.

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.

Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.

25.

Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome.

Pareto D, Sastre-Garriga J, Alberich M, Auger C, Tintoré M, Montalban X, Rovira À.

Neuroradiology. 2019 Jun;61(6):667-674. doi: 10.1007/s00234-019-02191-3. Epub 2019 Mar 5.

PMID:
30834955
26.

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.

Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, Galán I, Río J, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez B, Midaglia L, Mulero P, Mitjana R, Auger C, Sastre-Garriga J, Montalban X, Tintoré M.

Neurology. 2019 Mar 26;92(13):e1507-e1516. doi: 10.1212/WNL.0000000000007178. Epub 2019 Mar 1.

27.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

28.

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.

Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR, Castilló J, Mulero P, Vidal-Jordana A, Arrambide G, Rodriguez-Acevedo B, Sastre-Garriga J, Río J, Comabella M, Galán I, Tintoré M, Montalbán X.

Neurology. 2019 Feb 5;92(6):296-298. doi: 10.1212/WNL.0000000000006801. Epub 2018 Dec 26. No abstract available.

PMID:
30587519
29.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

30.

Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.

Costa C, Eixarch H, Martínez-Sáez E, Calvo-Barreiro L, Calucho M, Castro Z, Ortega-Aznar A, Ramón Y Cajal S, Montalban X, Espejo C.

Am J Pathol. 2019 Mar;189(3):665-676. doi: 10.1016/j.ajpath.2018.11.007. Epub 2018 Dec 13.

31.

Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis.

Amezcua L, Beecham AH, Delgado SR, Chinea A, Burnett M, Manrique CP, Gomez R, Comabella M, Montalban X, Ortega M, Tornes L, Lund BT, Islam T, Conti D, Oksenberg JR, McCauley JL.

Ann Clin Transl Neurol. 2018 Sep 23;5(11):1362-1371. doi: 10.1002/acn3.646. eCollection 2018 Nov.

32.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
33.

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.

Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G.

Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12.

34.

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

Malhotra S, Villar LM, Costa C, Midaglia L, Cubedo M, Medina S, Fissolo N, Río J, Castilló J, Álvarez-Cermeño JC, Sánchez A, Montalban X, Comabella M.

J Neuroinflammation. 2018 Oct 26;15(1):296. doi: 10.1186/s12974-018-1336-9.

35.

The Multiple Sclerosis Care Unit.

Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G.

Mult Scler. 2019 Apr;25(5):627-636. doi: 10.1177/1352458518807082. Epub 2018 Oct 23.

36.

Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists.

Saposnik G, Montalban X, Selchen D, Terzaghi MA, Bakdache F, Montoya A, Fruns M, Caceres F, Oh J.

Front Neurol. 2018 Sep 24;9:781. doi: 10.3389/fneur.2018.00781. eCollection 2018.

37.

Multiple sclerosis: clinical aspects.

Oh J, Vidal-Jordana A, Montalban X.

Curr Opin Neurol. 2018 Dec;31(6):752-759. doi: 10.1097/WCO.0000000000000622. Review.

PMID:
30300239
38.

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.

Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M.

J Neuroinflammation. 2018 Sep 14;15(1):265. doi: 10.1186/s12974-018-1307-1.

39.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313.

40.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9.

PMID:
30155789
41.

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

Midaglia L, Gratacòs M, Caronna E, Raguer N, Sastre-Garriga J, Montalban X, Tintoré M.

Neurology. 2018 Sep 25;91(13):622-624. doi: 10.1212/WNL.0000000000006251. Epub 2018 Aug 24. No abstract available.

42.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.

43.

Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care.

Saposnik G, Tobler PN, Caceres F, Terzaghi MA, Ruff C, Maurino J, Fruns Quintana M, Oh J, Montalban X, Mamdani M.

Front Neurol. 2018 Jul 10;9:522. doi: 10.3389/fneur.2018.00522. eCollection 2018.

44.

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477. doi: 10.1212/NXI.0000000000000477. eCollection 2018 Sep.

45.

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

Leussink VI, Montalban X, Hartung HP.

CNS Drugs. 2018 Jul;32(7):637-651. doi: 10.1007/s40263-018-0536-2. Review.

PMID:
29992409
46.

Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.

Fissolo N, Cervera-Carles L, Villar Guimerans LM, Lleó A, Clarimón J, Drulovic J, Dujmovic I, Voortman M, Khalil M, Gil E, Navarro L, Álvarez-Cermeño JC, Montalban X, Comabella M.

Mult Scler. 2019 Oct;25(11):1535-1538. doi: 10.1177/1352458518786055. Epub 2018 Jul 9.

PMID:
29985092
47.

Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain.

Quintana E, Coll C, Salavedra-Pont J, Muñoz-San Martín M, Robles-Cedeño R, Tomàs-Roig J, Buxó M, Matute-Blanch C, Villar LM, Montalban X, Comabella M, Perkal H, Gich J, Ramió-Torrentà L.

Eur J Neurol. 2018 Sep;25(9):1189-1191. doi: 10.1111/ene.13687. Epub 2018 Jun 22.

PMID:
29797629
48.

Ocrelizumab: a new milestone in multiple sclerosis therapy.

Mulero P, Midaglia L, Montalban X.

Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025. doi: 10.1177/1756286418773025. eCollection 2018. Review.

49.

Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.

Marrie RA, Montalban X.

Mult Scler. 2018 Apr;24(5):558-562. doi: 10.1177/1352458518767323. No abstract available.

PMID:
29692224
50.

Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.

Saposnik G, Montalban X.

Front Neurol. 2018 Mar 20;9:174. doi: 10.3389/fneur.2018.00174. eCollection 2018.

Supplemental Content

Loading ...
Support Center